Drug intelligence / Profile preview

human umbilical cord mesenchymal stem cells (Hornetcorn Biotech)

Development stage
Unknown
Lead developer
Hornetcorn Biotech
Modality
Stem Cell Therapies → Cell Therapies
Administration
Intravenous
01

Overview

Human umbilical cord mesenchymal stem cells (hUC-MSCs) are multipotent stromal cells derived from the Wharton's jelly of the human umbilical cord. Developed by Shenzhen Hornetcorn Bio-technology, these cells are being investigated for the treatment of pneumoconiosis, a chronic occupational lung disease characterized by inflammation and progressive fibrosis due to mineral dust inhalation. The therapeutic mechanism of hUC-MSCs involves their ability to home to injured lung tissue and exert immunomodulatory and anti-fibrotic effects through paracrine signaling. By secreting various bioactive factors, such as anti-inflammatory cytokines and growth factors, hUC-MSCs aim to suppress chronic pulmonary inflammation and inhibit the activation of myofibroblasts, potentially slowing the progression of lung scarring and improving respiratory function. The product is currently undergoing Phase I clinical evaluation to assess its safety and preliminary efficacy in this patient population.

Other names
hUC-MSCsumbilical cord-derived mesenchymal stem cells

Beyond the preview

Go deeper on human umbilical cord mesenchymal stem cells (Hornetcorn Biotech).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on human umbilical cord mesenchymal stem cells (Hornetcorn Biotech).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call